Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary prevention of atopy and asthma with house dust mite sublingual immunotherapy in high-risk infants
2009-015679-28Phase 2Completed
- Sponsor
- University Hospital Southampton
- Start
- Mar 2010
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Atopy and asthma comparing SIW08 active treatment with Placebo (2 arms). Primary endpoint: Cumulative prevalence of sensitisation to house dust mite over the 12 months intervention period. Started Mar 2010; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
Atopyasthma
Beyond the preview
Go deeper on 2009-015679-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015679-28.